Login / Signup

Targeting respiratory microbiomes in COPD and bronchiectasis.

Sanjay Haresh ChotirmallMicheál Mac AogáinPei Yee TiewTavleen Kaur JaggiJayanth Kumar NarayanaShivani SinghPhilip M HansbroLeopoldo N Segal
Published in: Expert review of respiratory medicine (2024)
Given the heterogeneity in microbiome composition and its pivotal role in disease development and progression, a shift toward microbiome-directed therapeutics is appealing. This transition, from traditional 'pathogen-centric' diagnostic and treatment modalities to those acknowledging the microbiome, can be enabled by evolving cross-disciplinary platforms which have the potential to accelerate microbiome-based interventions into routine clinical practice. Bridging the gap between comprehensive microbiome analysis and clinical application, however, remains challenging, necessitating continued innovation in research, diagnostics, trials and therapeutic development pipelines.
Keyphrases
  • clinical practice
  • cystic fibrosis
  • chronic obstructive pulmonary disease
  • physical activity
  • single cell
  • lung function
  • drug delivery
  • human health
  • data analysis